My laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine and eradication strategies. We have also recently begun evaluating Zika virus vaccine candidates. We received three NIH U19 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program grants in 2005, 2008, and 2012 to construct alternative serotype adenovirus vaccine vectors and to evaluate these vaccine candidates in preclinical and clinical studies. Ten phase 1 and phase 2a clinical trials have been conducted with these vectors in the United States, East Africa, South Africa, and Southeast Asia. We also received two NIH U19/UM1 grants in 2011 and 2016 to establish a consortium for innovative AIDS research in nonhuman primates and an NIH UM1 Martin Delaney Collaboratory grant in 2016 to develop HIV-1 cure strategies. In addition, we received four Gates Foundation consortium grants to develop replicating adenovirus vectors, nonhuman primate adenovirus vectors, novel Env protein immunogens, and therapeutic broadly neutralizing monoclonal antibodies. My group is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD), the NIH Center for HIV/AIDS Vaccine Immunology and Immunogen Design (CHAVI-ID), and the Ragon Institute of MGH, MIT, and Harvard. I currently serve as Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School.